Leukemia
Identifying the risk factors for infection may allow preventive measures to be taken to protect patients. Read More ›
Oral targeted therapies have revolutionized treatment for patients with CLL but ensuring that they are taken as prescribed is crucial to achieving optimal outcomes. Read More ›
Copay assistance coupons and copay adjustment programs put patients in the middle of healthcare cost-saving measures. Read More ›
Currently, many effective, well-tolerated treatments exist, with high expectations for new drugs and regimens to be developed and approved in the near future. Read More ›
A literature review found a set of physical, psychological, social, and spiritual topics that could be used to better educate patients throughout their CLL treatment journey. Read More ›
COVID-19 vaccination is generally safe for immunocompromised patients, including those with CLL, although the efficacy is substantially lower than in healthy individuals. Read More ›
Cell-based assays and animal data suggest that ZN-d5 may be a tolerable and effective treatment for patients with leukemias and lymphomas. Read More ›
The first head-to-head trial of these drugs shows comparable efficacy with a better cardiovascular safety profile for acalabrutinib. Read More ›
A recent study provides some of the first data on COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Read More ›
Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia. Read More ›